prothipendyl 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
vasodilators 2315 303-69-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prothipendyl hydrochloride
  • prothipendyl
  • phrenotropin
  • dominal
  • prothipendyl HCl
a neuroleptic azaphenothiazine; RN given refers to parent cpd
  • Molecular weight: 285.41
  • Formula: C16H19N3S
  • CLOGP: 4.13
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 19.37
  • ALOGS: -3.35
  • ROTB: 4

Drug dosage:

DoseUnitRoute
0.24 g O
0.24 g P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.498 Moderate 0.72
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.611 Moderate 0.72
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 33.420 10^-6 cm/s Moderate 0.72
dh-clint Dog hepatocyte intrinsic clearance 143.219 uL/min/10^6 cells Moderate 0.72
dppb Dog plasma protein binding (% unbound) 36.740 % Moderate 0.72
fcs-ppb Fetal calf serum protein binding (% unbound) 35.780 % Moderate 0.72
herg hERG pIC50 5.410 pIC50 Moderate 0.72
hh-clint Human hepatocyte intrinsic clearance 15.453 uL/min/10^6 cells Moderate 0.72
hlm-clint Human liver microsomal intrinsic clearance 33.497 uL/min/mg protein Moderate 0.72
hppb Human plasma protein binding (% unbound) 36.470 % Moderate 0.72
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MARK4,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK 42
kinase-selectivity-class STK33 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.631 Moderate 0.72
mh-clint Mouse hepatocyte intrinsic clearance 371.535 Moderate 0.72
mppb Mouse plasma protein binding (% unbound) 44.610 Moderate 0.72
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.722 Moderate 0.72
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 52.190 % Moderate 0.72
rh-clint Rat hepatocyte intrinsic clearance 287.078 uL/min/10^6 cells Moderate 0.72
rh-fuinc Rat hepatocyte fraction unbound in incubation 73.940 % Moderate 0.72
rppb Rat plasma protein binding (% unbound) 41.730 % Moderate 0.72
solubility-dd Solubility at pH 7.4 in DMSO 961.612 uM Moderate 0.72

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 99.83 48.85 48 734 276405 90351260
Disorientation 63.87 48.85 21 761 44093 90583572
Helplessness 56.15 48.85 8 774 299 90627366
Labelled drug-drug interaction medication error 52.22 48.85 14 768 14568 90613097
Skin maceration 50.59 48.85 7 775 211 90627454

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Labelled drug-drug interaction medication error 60.21 59.57 18 638 15564 42605115

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Labelled drug-drug interaction medication error 111.12 45.50 31 1191 29271 110558806
Drug interaction 99.71 45.50 64 1158 500119 110087958
Disorientation 91.76 45.50 33 1189 70638 110517439
Galactorrhoea 54.90 45.50 12 1210 4143 110583934
Helplessness 52.41 45.50 8 1214 374 110587703
Restlessness 50.20 45.50 20 1202 56239 110531838
Skin maceration 48.81 45.50 7 1215 212 110587865
General physical health deterioration 46.58 45.50 38 1184 425257 110162820

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AX07 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Other antipsychotics
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent

Related Drugs by ATC class:

N05AX Other antipsychotics 11 drugs
aripiprazolebrexpiprazolecariprazineiloperidonemosapraminepaliperidonepimavanserinrisperidonetrospiumxanomelinezotepine

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.01 Basic
pKa2 2.74 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D07313 KEGG_DRUG
1225-65-6 SECONDARY_CAS_RN
C0139007 UMLSCUI
CHEBI:135182 CHEBI
CHEMBL2111030 ChEMBL_ID
CHEMBL2107124 ChEMBL_ID
DB12958 DRUGBANK_ID
C069248 MESH_SUPPLEMENTAL_RECORD_UI
14670 PUBCHEM_CID
691 INN_ID
5O6VWA87VA UNII
236710 RXNORM
006649 NDDF
006650 NDDF
1000311000202102 SNOMEDCT_US
27766008 SNOMEDCT_US

Pharmaceutical products:

None